Fabmid develops a cutting-edge non-viral vector combining the beneficial features of a circular DNA molecule and protein molecules:
The circular DNA molecule contains the gene of interest and nucleotide sequences for the therapeutic effect in the patient's cells. Unlike other vectors, it does not contain toxic or damaging DNA sequences, such as antibiotic resistance genes.
The protein part is designed to boost vector penetration into targeted patient's cells.
Fabmid is developing a vector both easy to produce and with all the properties required from a good vector: high cell transfection efficiency, low toxicity, high stability and selectivity. As a result, it helps reduce the cost and length of gene therapy R&D programs, as well as manufacturing costs.
For what kind of therapy is Fabmid's vector suited?
Fabmid’s vector is suited for both in vivo gene therapy and ex vivo gene therapy (gene modified cell therapy). In particular, it can include an antibody targeting a specific cells receptors.
Why is it cheaper and easier to produce than viral vectors?
Our vector is manufactured from a DNA plasmid, requiring a few simple additional steps.
Production of plasmids is a well-known, standardized process. Plasmids manufacturing costs are thus lower than viral vectors production. Production scale-up, required for commercialization, is much easier for plasmids than for viral vectors.
Why is it safer than viral vectors?
The main drawbacks of using virus vectors are the immunogenicity and cytotoxicity risks. Non-viral vectors are known for their greater bio-safety. Additionally, thanks to the high gene delivery efficiency, less vectors are necessary for a treatment, which further reduces undesired immune response risks.
Moreover, because Fabmid’s vector can be transfected without nano-carriers such as lipoplexes, potential toxicity of such carriers is removed.